Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma
Year: 2018
Type: article
Abstract: To the Editor: Desmoplastic melanomas (4% of melanomas) are characterized by spindled melanocytes, collagenous or desmoplastic stroma, and an intense inflammatory response.1 Desmoplastic melanomas carry a high mutation burden compared generally with other cancers.2 Programmed cell death 1 protein (PD-1) inhibitors have been granted Food and Drug Administration approval for advanced melanoma as first-line therapy.3 In addition, a high mutation burden has been demonstrated as an effective predictor of response to checkpoint inhibitors, likely due to the increased neoepitope generation and cytotoxic T-cell activation.
Institutions: Centre National de la Recherche Scientifique, Hôpital Pontchaillou, Institut de génétique et de développement de Rennes, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Foundation Medicine (United States), City Of Hope National Medical Center, City of Hope, Hadassah Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Moffitt Cancer Center, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Albany Medical College, Albany Medical Center Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,200
OpenAlex ID: W2904200760